OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma
- 1 September 2017
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 140, 16-27
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (30901778)
- National Major Science and Technology Projects of China (20092X09102-154)
This publication has 40 references indexed in Scilit:
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- mTOR: from growth signal integration to cancer, diabetes and ageingNature Reviews Molecular Cell Biology, 2010
- Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and StressMolecular Cell, 2010
- mTOR and cancer: many loops in one pathwayCurrent Opinion in Cell Biology, 2010
- mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 SignalingMolecular and Cellular Biology, 2010
- mTOR mediated anti-cancer drug discoveryDrug Discovery Today: Therapeutic Strategies, 2009
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their SurvivalCell, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005